CN1537545A - Sugar-free type blood-fat-lowering granule, and its prepn. method - Google Patents
Sugar-free type blood-fat-lowering granule, and its prepn. method Download PDFInfo
- Publication number
- CN1537545A CN1537545A CNA031089720A CN03108972A CN1537545A CN 1537545 A CN1537545 A CN 1537545A CN A031089720 A CNA031089720 A CN A031089720A CN 03108972 A CN03108972 A CN 03108972A CN 1537545 A CN1537545 A CN 1537545A
- Authority
- CN
- China
- Prior art keywords
- radix
- blood fat
- type blood
- granule
- fat reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims description 27
- 238000000034 method Methods 0.000 title description 15
- 235000003599 food sweetener Nutrition 0.000 claims abstract 2
- 239000003765 sweetening agent Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000008280 blood Substances 0.000 claims description 41
- 210000004369 blood Anatomy 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 29
- 230000001603 reducing effect Effects 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 17
- 235000000346 sugar Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 44
- 239000000463 material Substances 0.000 abstract description 11
- 241000219780 Pueraria Species 0.000 abstract description 2
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 238000000605 extraction Methods 0.000 description 17
- 201000005577 familial hyperlipidemia Diseases 0.000 description 15
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 13
- 239000012567 medical material Substances 0.000 description 13
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- -1 hydroxyanthraquinone glycoside compound Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229930188824 alisol Natural products 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000013547 stew Nutrition 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- BTLXPCBPYBNQNR-UHFFFAOYSA-N 1-Hydroxyanthraquinone Natural products O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2O BTLXPCBPYBNQNR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001113926 Gelsemium Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- YEZWWUMWIFKEQM-UHFFFAOYSA-N O.OC.ClC(Cl)Cl.CCOC(C)=O Chemical compound O.OC.ClC(Cl)Cl.CCOC(C)=O YEZWWUMWIFKEQM-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A sugar-free blood-fat lowering Chinese medicine in the form of particles is prepared from 5 Chinese-medicinal materials including pueraria root, haw, fleece flower root, Chinese angelica root, etc through extracting their active components, adding sugar-free sweetener and granulating.
Description
Invention field
The present invention relates to a kind of Sugarless type Chinese medicine blood fat reducing granule dosage form, the invention still further relates to the preparation method of this granule.
Background technology
Hyperlipemia is divided into former and secondary two big classes clinically, is the consequence of lipid and lipoprotein metabolism disorder in the numerous disease.Therefore, research and treatment hyperlipemia have important relationship with the control numerous disease.Particularly hyperlipemia causes atherosclerosis, causes cordis and cerebral accident, and the state of an illness is dangerous, prognosis mala.At present, all there is bigger side effect in Chang Yong fat-reducing medicament clinically.And life-time service, the part medicine can be big because of gastrointestinal reaction, causes consequences such as fatsoluble vitamin malabsorption.In addition, because crowd's individual variation is bigger, bigger different and difference is also deposited in the curative effect and the reaction of medicine.And the treatment by Chinese herbs hyperlipemia has certain curative effect, is better than Western medicine aspect toxic and side effects, is fit to take for a long time, discloses a kind of capsule for descend of blood fat as CN1263772A, and it is made up of Fructus Crataegi, the Radix Polygoni Multiflori, Rhizoma Alismatis, Radix Bupleuri, Radix Salviae Miltiorrhizae, Pericarpium Citri Reticulatae, Semen Raphani, Radix Curcumae; Have that strengthening spleen, tonifying kidney is soothing the liver, promoting blood circulation to remove stagnancy blood stasis dispelling effect, treatment fatty liver, hyperlipemia total effective rate reach 85%; CN1364512A discloses a kind of defatting and poison expelling capsule, select Radix Et Rhizoma Rhei, the Radix Polygoni Multiflori, Semen Cassiae, Rhizoma Alismatis for use, through ethanol extraction, Fructus Gardeniae, Radix Bupleuri, Rhizoma Curcumae, Fructus Crataegi, Herba Artemisiae Scopariae water are carried, make capsule, it can treat and prevent hyperlipemia, blood fat reducing, elimination hemorheology obstacle, and instant effect, cure rate height and treatment cycle are short.
CN1156601A discloses a kind of lipid lowerers, it is to select Rhizoma Polygoni Cuspidati, Radix Curcumae, Pericarpium Citri, Folium Nelumbinis, Fructus Crataegi, Radix Astragali, Fructus Schisandrae Chinensis, Rhizoma Atractylodis Macrocephalae (parched), Fructus Ligustri Lucidi, Herba Cistanches, Herba Epimedii, Radix Et Rhizoma Rhei, Rhizoma Alismatis for use, mix and decoct, concentrate and make, have soothing liver and strengthening spleen, tonify Qi of the kidney, blood circulation invigorating efficacies, can reduce the content of cholesterol and triglyceride in the blood, increase hdl concentration, quicken the curative effect of lipid metabolism.However, the curative effect of above-mentioned these medicines is owing to lack complete testing data and the evaluation of objective concrete experimental data, so all remain further to be investigated.So still need at present according to the Chinese medicine theory, in conjunction with contemporary Chinese medicine research achievement, dialectical with debate disease and combine, select suitable drug matching to use, develop a kind of definite lipid reducing and regulating effect that both had, side effect and reacting phase are to less, be beneficial to for a long time again and take, while scalable human body body function and equilibrated novel purely natural Chinese medicine, this is to the treatment hyperlipemia, and prevention cardiovascular and cerebrovascular disease and senile pathological changes have significance.A kind of Chinese traditional medicines depressing lipid granule of Sugarless type especially, is provided.
With single medical material such as Fructus Crataegi, Radix Puerariae, Rhizoma Alismatis, fleece flower root for treating hyperlipemia, coronary heart disease and atherosclerosis report is arranged all.With these medicines serves as main form compound recipe to be used for the treatment of cardiovascular disease more common, from these medicines, can extract the effective site or the effective ingredient of the sick disease of treatment painstaking effort, as Fructus Crataegi ketone treatment angina pectoris, Fructus Pyri Pashiae extractum treatment hyperlipemia, Radix Puerariae flavone treatment angina pectoris, Radix Polygoni Multiflori extractum treatment hypercholesterolemia, injection treatment coronary heart disease, Radix Angelicae Sinensis injection treatment thromboangiitis, ferulic acid anticoagulant, Rhizoma Alismatis saponins for treating hyperlipemia.But up to now, do not find these several herbal medicines are combined the particulate bibliographical information of Sugarless type blood fat reducing that hyperlipemia is more effectively treated in preparation.
Summary of the invention
Purpose of the present invention just provides a kind of Sugarless type blood fat reducing granule of determined curative effect.
Another object of the present invention provides the particulate preparation method of Sugarless type blood fat reducing.
The particulate active component of Sugarless type blood fat reducing of the present invention is made up of following raw materials by weight percent water extract and 10-20% Rhizoma Alismatis powder:
Radix Puerariae 25-35, Fructus Crataegi 25-35%, Radix Polygoni Multiflori 10-15% and Radix Angelicae Sinensis 5-10%.
Water extract and 10-15% Rhizoma Alismatis powder that preferred active component is made by following raw materials by weight percent are formed:
Radix Puerariae 28-33%, Fructus Crataegi 29-34%, Radix Polygoni Multiflori 10-13% and Radix Angelicae Sinensis 5-8%.
More preferably water extract and 15% Rhizoma Alismatis powder made by following raw materials by weight percent of active component formed:
Radix Puerariae 32%, Fructus Crataegi 33%, Radix Polygoni Multiflori 12% and Radix Angelicae Sinensis 8%.
If Fructus Crataegi is selected Fructus Crataegi (parched) for use in above-mentioned raw materials, Radix Polygoni Multiflori is selected Radix Polygoni Multiflori Preparata for use, and curative effect is better.Fructus Crataegi (parched): according to appendix IID of 95 editions pharmacopeia (medicinal material processing general rule three. big gun is processed 1. and is fried) in fry method: get clean Fructus Crataegi and put in the heat pot, fry to complexion changed when dark, take out, cool, get final product with slow fire; Radix Polygoni Multiflori Preparata: according to appendix IID of 95 editions pharmacopeia (medicinal material processing general rule three. big gun is processed 7. and is stewed) stew method: get clean Radix Polygoni Multiflori pieces, mix thoroughly, put in the porcelain container with decoction of black soybean, airtight, stew when juice exhausts with steam heated, cool, taking-up, drying gets final product.
Sugarless type blood fat reducing granule of the present invention is selected promoting digestion and removing stagnation, blood circulation promoting and blood stasis dispelling, strengthening spleen, tonifying kidney, clearing away heat-damp and promoting diuresis medicine prescription for use.Be monarch drug with Fructus Crataegi (parched), Radix Puerariae in the side, removing food stagnancy blood stasis removing, invigorating the spleen and regulating the stomach; Rhizoma Alismatis is a minister, assists monarch drug, makes its blood stasis dispelling blood and does not hinder fresh blood, and dissipating depression of QI gas and do not hinder healthy energy makes heresy that outlet be arranged, jointly at primary symptom; Assistant is with Radix Polygoni Multiflori Preparata, merit in the replenishing essence the kidney invigorating, the liver benefiting nourishes blood; Make with Radix Angelicae Sinensis, can enrich blood invigorate blood circulation, promoting tissue regeneration by removing blood stasis, make blood fortune unobstructed.More than all medicines share, reinforcing and reducing are also executed, the merit that row stagnates and to promote blood circulation is played in treating both the principal and the secondary aspects of a disease at the same time altogether.
The development of the particulate active component of Sugarless type blood fat reducing of the present invention is the clinical experience side that comes from distinguished veteran doctors of TCM, former side's decoction treatment hyperlipemia determined curative effect.In order to keep the curative effect of former decoction, we must carry out the selection of dosage form and the research of technological parameter.Make granule in view of Chinese medicine granules (electuary) preparation technology adopts water boiling and extraction gained extractum to add adjuvant more, only need boiled water to take after mixing it with water, both overcome the trouble that decocts, can keep the characteristics of decoction again, thereby also just keep clinical efficacy; In addition, consider that this product indication is a hyperlipemia, the patient avoids sugar more, therefore, can not be that adjuvant is made particulate method by traditional electuary sugaring part again, but according to character of medicinal material, select starch-containing many, the medical material that is easy to pulverize (Rhizoma Alismatis) breaks into fine powder and directly is used as medicine, and both as auxiliary material excipient, is again principal agent, make the outstanding property granule of sugar-free, dosage is little, stores and transports, carries, uses all very convenient, is applicable to clinical needs more.
Sugarless type blood fat reducing granule unique processing process makes to have comprised the main active component of crude drug in its preparation, as flavone, pentacyclic triterpenoid saponin etc.The sugar-free dosage form has been avoided the interference of drug excipient to curative effect itself, is particularly suitable for the patient who needs strict control sugar to take in.The blood viscosity lowering that the blood fat reducing granule possesses, effects such as anticoagulant are regulated hemorheology status and are also played good coordinative role improving the body microcirculation.
Blood fat reducing granule of the present invention is to cure mainly physicochemical property with active chemical according to each medical material function in the prescription, and medical material is divided into two groups, adopts different PROCESS FOR TREATMENT.Select Rhizoma Alismatis directly to beat powder simply and be used as medicine, so that the medicine active substance keeps and grain forming.Rhizoma Alismatis property is sweet, cold, and effect is diuresis, clearing away damp-heat, and blood fat reducing and anti-fatty liver cure mainly dysuria and hyperlipemia, is one of principal agent in the prescription.The main chemical compositions of Rhizoma Alismatis contains the derivant of multiple tetracyclic triterpene keto-alcohol such as alisol, alisol acetas, choline, lecithin etc.Rhizoma Alismatis is the tubers medical material, and behind the chip drying, quality is hard, and mealiness is stronger, contains a large amount of starch, and very easily crushing screening also can be avoided loss of effective components in the leaching process simultaneously; If water decocts then very easily gelatinizing, it is directly beaten powder be used as medicine, as excipient replacement Icing Sugar, starch or dextrin,, the single dose volume is reduced greatly with the molding of absorption extractum system soft material, reach curative effect height, requirement that dosage is little.
Select Radix Puerariae, Fructus Crataegi, Radix Polygoni Multiflori and Radix Angelicae Sinensis four Chinese medicine material compound recipe water extract-alcohol precipitation to be used as medicine.The sweet cold of Radix Puerariae has expelling pathogenic factors from muscles for reducing heat, a function of the rash of promoting the production of body fluid, yang invigorating antidiarrheal.Its main chemical compositions is flavones ingredients such as puerarin, daidzin, has tangible effect for reducing blood fat, in more soluble in water, the alcohol; Radix Puerariae is a ratio of rhizome medicinal material, and the fibre-bearing amount is big, is difficult for pulverizing.The main chemical compositions of Fructus Crataegi is Crataegolic acid, multivitamin, sugar, flavone, glycoside, tannin, protein etc., all is soluble in hot water and the alcohol; Fructus Crataegi is the fruit medical material, and quality is softer, be difficult for to pulverize, and adopts aqueous extraction-alcohol precipitation technology, can remove impurity such as tannin, and has kept effective ingredient such as Crataegolic acid.Radix Polygoni Multiflori (system) property hardship, sweet, puckery temperature have the function of invigorating the liver and kidney, benefiting essence-blood, cholesterol reducing and beta lipoprotein, Wu Sifa, cure mainly blood deficiency and yellow complexion and hyperlipemia etc.; It mainly contains hydroxyanthraquinone glycoside compound such as chrysophanic acid, emodin, chrysophanol and glucoside chemical compound, and polarity is bigger, can be dissolved in hot water and alcohols; Radix Polygoni Multiflori is a tuber class medical material, and system back quality is softer, is difficult for pulverizing.Radix Angelicae Sinensis is sweet, hot, warm, and effects such as having enriches blood invigorates blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation are messenger drug in the side; Its main component has ferulic acid, nicotinic acid, succinic acid, aminoacid etc., is soluble in hot water and alcohol; In addition, when giving back volatile ingredients such as containing ligustilide, sesquiterpenoids, but content seldom.For making technology not too complicated, during water extract-alcohol precipitation, specific examples of such components has partial loss, because of former side's decoction also extracts for decocting, does not affect the treatment from seeing clinically.
To sum up by to the flavour of a drug analysis of physical and chemical property, medical material is merged back decocting cooking method extract its aqueous soluble active constituent, the water-solubility impurity of Ti Chuing simultaneously, it is scientific and reasonable that the reuse ethanol precipitation is removed.
Active component of the present invention can also be made granule with pharmaceutically acceptable excipient.This product is a blood fat reducing class medicine, need make Sugarless type.Excipient adopts medical material fine powder (seeing above-mentioned).Because this product flavour of a drug are more, mouthfeel is relatively poor, so adjuvant is only considered correctives.Screening from sweeting agent protein sugar commonly used, stevioside etc. determines with the protein sugar to be that adjuvant is comparatively suitable, and addition the results are shown in Table 1 with the evaluation of experiment mouthfeel.
(% is g/g) with the mouthfeel evaluation for table 1 protein sugar addition
| Addition | ?????2.5????????5.5??????????8.5??????10.0 |
| Mouthfeel is estimated | Flavour of a drug heavily have flavour of a drug, the better mouthfeel of the slightly sweet sweet several no sweet taste mouthfeels sweet taste of generally having a surplus |
In view of the above, supplementary product consumption is selected protein sugar 5.5% (g/g).
Below we have carried out screening study to process conditions.
(1) pulverizing of Rhizoma Alismatis: because Rhizoma Alismatis is used as medicine for directly breaking into fine powder, can directly influence the quality and the stability of finished product, therefore to aspects such as quality of medicinal material, water content, hygiologys higher requirement should be arranged all, the fresh dried product that should select free from insect pests to go mouldy, clean with drinking water earlier, feed intake after 60 ℃ of oven dry again, to reduce contamination by micro as far as possible.Be to guarantee the stability of the quality of the pharmaceutical preparations and technology, we investigate the flour extraction that Rhizoma Alismatis crosses behind 100 mesh sieves, the results are shown in Table 2.
Table 2 Rhizoma Alismatis is pulverized the back flour extraction
First second batch the 3rd batch of lot number
Flour extraction (%) 94.3 93.5 93.9
The result shows: the Rhizoma Alismatis medical material directly breaks into fine powder, and flour extraction is higher, and technology is feasible rational.
(2) water boiling and extraction of four flavors such as Radix Puerariae: Radix Puerariae, Fructus Crataegi, Radix Polygoni Multiflori, Radix Angelicae Sinensis four flavor compound recipes merge, with the water boiling and extraction effective ingredient, for making this operation scientific and reasonable, we study extraction process by water with positive arrearing optimization in experiment, and serve as to investigate index with the extraction ratio of puerarin in the monarch drug Radix Puerariae, in the hope of filtering out optimum process condition.EXPERIMENTAL DESIGN adopts L
9(3
4) orthogonal table, with extraction time, extraction time, an extraction water yield type clothing factor, each factor is chosen 3 levels commonly used and is investigated.The four Chinese medicine material of getting 1/3 recipe quantity is total to 1473g, and totally 9 parts, test by table, the results are shown in Table 3,4,5.Index components content of puerarin assay method is as follows:
Get each time test extracting solution an amount of (being equivalent to Radix Puerariae medical material 2g), precision is measured, and water-soluble evaporate to dryness, residue extract with ethyl acetate Ying Shi and refluxed 6 hours, behind the extracting solution evaporate to dryness, residue adds dissolve with methanol, quantitatively is transferred in the 5ml measuring bottle, add methanol to scale, shake up, extracting solution is as test sample liquid; Other gets the puerarin reference substance, adds methanol and makes the solution that every ml contains 1.0mg, and product liquid according to thin layer chromatography scanning (57 pages of appendix of 90 editions pharmacopeia) test, is drawn test sample liquid 5ul in contrast, reference substance liquid 1ul, and 4ul puts in same silica gel G F respectively
2541On the lamellae, (15: 40: 22: lower floor's solution 10) was developing solvent, launched, and took out, and dried wavelength X with chloroform-ethyl acetate-methanol-water
S=250nm, λ
R=250nm carries out sweep measuring, calculates, and promptly draws the content that is converted to medical material.
Table 3 water extraction factor level table
Table 4 water extraction orthogonal experiments
Table 5 test is through variance analysis
The mean square F value of soruces of variation sum of deviation square degree of freedom factor affecting
A 4.81 * 10
-32 2.40 * 10
-3Significantly 17.65 (P＜0.05)
B 1.38 * 10
-22 6.90 * 10
-3Significantly 50.73 (P＜0.05)
C 2.34 * 10
-32 1.17 * 10
-3Not 8.60 remarkable (P＞0.05)
E (error) 2.72 * 10
-42 1.36 * 10
-4
The above results the analysis showed that: each factor is all influential to the extraction content of puerarin, and size order is B＞A＞C, i.e. extraction time＞extraction time＞extraction water yield, the optimum combination condition B of three factors
3A
3C
2, because of the B factor has significance influence, thus must extraction 3 times, and A factor, C factor affecting are not remarkable.If each 2 hours, decocting time was long, consider from big production, during consumption energy consumption, during cost increases, so select A
2, promptly each 1.5 hours.For the reasonability and the operability of proof scheme, we respectively get the medical material of a recipe quantity again, to B
3A
3C
2(I) condition and B
3A
3C
2(II) the condition combination is carried out contrast test three times, is to investigate index equally with the puerarin content, and method of testing is the same, the results are shown in Table 6.
Table 6 different tests condition is (n=30) relatively
Puerarin content (%) extracted back puerarin content (%) before experimental condition extracted
B
3A
3C
2(I)?????0.260??????????????????0.239
B
3A
3C
2(II)????0.260??????????????????0.234
The result shows: two set conditions are to extracting the puerarin no significant difference, and the II group is lower than the I group slightly, but considers from the suitability for industrialized production angle, has shortened 1.5 hours man-hour, and it is less to extract the water yield, time-saving energy-saving, and production cost obviously reduces, and does not influence product quality again.Therefore determine B
3A
3C
2Condition is more suitable in suitability for industrialized production.Be Radix Puerariae, Fructus Crataegi, Radix Polygoni Multiflori, Radix Angelicae Sinensis four flavor water extraction 3 times, each 1.5 hours, amount of water was 8 times.
5. precipitate with ethanol impurity removal process: water extraction process has proposed the water soluble ingredient of each flavour of a drug, wherein macromolecular substances such as undesired impurities composition such as starch, tannin, polysaccharide, resin, albumen also are suggested, these compositions are not removed, will influence the moulding process and the quality of the pharmaceutical preparations, as color and luster, clarity, taste, hygroscopicity etc.We test and adopt an alcohol deposition method remove impurity.Get the same a collection of clear paste (d=1.05,60 ℃) of surveying Pueraria lobota gelsemium element, add ethanol and transfer to variable concentrations (60%, 70%, 80%), left standstill after stirring evenly 24 hours, behind the recovery ethanol, survey puerarin content again, the results are shown in Table 7.
The different alcohol precipitation concentrations of table 7 are to the influence of puerarin
Content (%) retention rate (%) before content (%) precipitate with ethanol before the alcohol precipitation concentration precipitate with ethanol
60％?????????0.234?????????????0.207?????????88.5
70％?????????0.234?????????????0.214?????????91.5
80％?????????0.234?????????????0.216?????????92.3
The result shows: during 70% and 80% precipitate with ethanol condition puerarin loss very little, and behind 60% precipitate with ethanol,, certain difficulty is arranged during filtration owing to still have partial impurities not eliminate, cause the puerarin loss.Though consider that 80% precipitate with ethanol condition is good, utilization rate is not high again behind the recovery ethanol, and production cost improves greatly.Therefore, consider, determine with 70% alcohol precipitation concentration to be optimum condition from the production angle.
6. preparations shaping technology
When carrying out the granule formation technology condition experiment, we design and adopt a granulation, when the medicinal liquid after being about to water extract-alcohol precipitation and reclaiming ethanol is condensed into different relative densities, grope with Rhizoma Alismatis fine powder mixing ratio relation, in the hope of finding out one-time formed steady-state conditions, result of the test sees Table 8.
The contrast of table 8 condition of molding
Relative density of medicine liquid (80 ℃) clear paste: fine powder (W: W) evaluation index
1.30-1.35 clear paste was feeding-up in 1: 1.50, dry powder is many, incomplete mixing.
1.25-1.30 add small amount of ethanol at 1: 1.35, mix homogeneously, soft material
Moderate good preparation.
1.20-1.25????????????????1∶1.20
Clear paste is rare excessively, and dry powder is few, can't granulate.
The result shows: concentrate back clear paste relative density when 1.25 (80 ℃), behind the adding Rhizoma Alismatis fine powder, put and fully be mixed into soft material in the blender, at this moment, clear paste and fine powder part by weight are about 1: 1.35.Because of this product is the suspension ability granule, other adds 2% hydroxymethyl starch with suspending, better effects if.Granulate the back after 60-80 ℃ of drying, cross 30 mesh sieves, packing gets final product.
7. hygiology control: because of this product contains crude drug powder, in preparation process, for the hygiology that guarantees preparation meets the requirements, we have adopted (1) strict control Rhizoma Alismatis quality of medicinal material, no infested, go mouldy; (2) water cleans the silt oven drying at low temperature, reduces microbial contamination as far as possible, and after beating powder and sieving, 80-90 ℃ of drying further sterilized; (3) used vessel and pulverizer in each operation are all cleaned with sterilization with 75% ethanol; (4) operate in sterilizing room or between purifying air; Add a small amount of 70% ethanol sterilization when (5) making soft material; (6) packaging material select the aluminium foil bag sealing, and will mix bacterium and mycete are controlled at bottom line.By the pilot product that said method is produced, can both be up to specification through health examination.
At last, we determine Sugarless type blood fat reducing granule preparing process of the present invention as follows: Rhizoma Alismatis powder is broken into powder, and standby; Radix Puerariae, Fructus Crataegi, the Radix Polygoni Multiflori, Radix Angelicae Sinensis four Chinese medicine material are decocted with water 2-3 time together, each 1-1.5 hour, merge decocting liquid, filter, filtrate concentrates, and adds ethanol and makes and contain the alcohol amount and reach 70%, leaves standstill, get supernatant and reclaim ethanol, ratio according to 5.5% (g/g) adds the concentrated clear paste that obtains of protein sugar, and qinghuo reagent adds Rhizoma Alismatis powder, mixed pelletization, drying, promptly.
Concrete embodiment
Embodiment 1
Take by weighing following raw materials in weight: Radix Puerariae 1667g, Fructus Crataegi (parched) 1667g, Rhizoma Alismatis 750g, Radix Polygoni Multiflori Preparata 667g, Radix Angelicae Sinensis 417g, standby;
Rhizoma Alismatis powder is broken into powder, Radix Puerariae, Radix Angelicae Sinensis, the Radix Polygoni Multiflori and Fructus Crataegi four flavors are decocted with water each 1.5 hours three times, collecting decoction filters, and filtrate is concentrated into relative density 1.05 (60 ℃), adding ethanol makes and contains alcohol amount and reach 70%, stir evenly, leave standstill, get supernatant and reclaim ethanol, ratio according to 5.5% adds protein sugar and is concentrated into the clear paste that relative density is 1.25-1.30 (80 ℃), qinghuo reagent adds the Rhizoma Alismatis fine powder, mixing, and drying obtains the 1000g granule.
Embodiment 2
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3500g, Fructus Crataegi (parched) 3500g, Rhizoma Alismatis 1000g, Radix Polygoni Multiflori Preparata 1500g, Radix Angelicae Sinensis 500g, standby;
Preparation process is with embodiment 1.
Embodiment 3
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3500g, Fructus Crataegi (parched) 2500g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1500g, Radix Angelicae Sinensis 1000g, standby;
Preparation process is with embodiment 1.
Embodiment 4
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3200g, Fructus Crataegi (parched) 3300g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1200g, Radix Angelicae Sinensis 800g, standby;
Preparation process is with implementing 1.
Embodiment 5
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3100g, Fructus Crataegi (parched) 3400g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1200g, Radix Angelicae Sinensis 800g, standby;
Preparation process with embodiment 1.
Embodiment 6
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3300g, Fructus Crataegi (parched) 3400g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1300g, Radix Angelicae Sinensis 500g, standby;
Preparation is with the step of embodiment 1.
Claims (9)
1. Sugarless type blood fat reducing granule, it is made up of active component and/or sugar-free sweetener, and wherein active component is made up of following raw materials by weight percent water extract and 10-20% Rhizoma Alismatis powder:
Radix Puerariae 25-35%, Fructus Crataegi 25-35%, Radix Polygoni Multiflori 10-15% and Radix Angelicae Sinensis 5-10%.
2. according to the described Sugarless type blood fat reducing of claim 1 granule, wherein water extract and the 10-15% Rhizoma Alismatis powder made by following raw materials by weight percent of active component formed:
Radix Puerariae 28-33%, Fructus Crataegi 28-33%, Radix Polygoni Multiflori 11-14% and Radix Angelicae Sinensis 6-9%.
3. according to the described Sugarless type blood fat reducing of claim 2 granule, wherein water extract and 15% Rhizoma Alismatis powder made by following raw materials by weight percent of active component formed:
Radix Puerariae 32%, Fructus Crataegi 32%, Radix Polygoni Multiflori 13% and Radix Angelicae Sinensis 8%.
4. according to any one described Sugarless type blood fat reducing granule of claim 1-3, wherein Fructus Crataegi is used Fructus Crataegi (parched) in the raw material, the Radix Polygoni Multiflori Radix Polygoni Multiflori Preparata.
5. according to any one described Sugarless type blood fat reducing granule among the claim 1-4, wherein said sugar-free correctives is protein sugar or stevioside.
6. according to the described Sugarless type blood fat reducing of claim 5 granule, wherein the sugar-free correctives is a protein sugar.
7. according to the described Sugarless type blood fat reducing of claim 6 granule, wherein the content of protein sugar is 5.5% (g/g).
8. the particulate preparation method of any one described Sugarless type blood fat reducing among the claim 1-7, it comprises the following steps: to take by weighing raw material, Rhizoma Alismatis powder is broken into powder, Radix Puerariae, Radix Angelicae Sinensis, the Radix Polygoni Multiflori and Fructus Crataegi four flavors are decocted with water three times, each 1.5 hours, collecting decoction filters, and it is 1.05 that filtrate is concentrated into 60 ℃ of survey relative densities, adding ethanol makes and contains alcohol amount and reach 70%, stir evenly, leave standstill, get supernatant and reclaim ethanol, adding protein sugar is concentrated into 80 ℃ to survey relative densities is the clear paste of 1.25-1.30, qinghuo reagent adds the Rhizoma Alismatis fine powder, mixing, promptly.
9. according to the described Sugarless type blood fat reducing of claim 8 preparation method of granules, wherein the protein sugar addition is 5.5% (g/g).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03108972 CN1291709C (en) | 2003-04-15 | 2003-04-15 | Sugar-free type blood-fat-lowering granule, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03108972 CN1291709C (en) | 2003-04-15 | 2003-04-15 | Sugar-free type blood-fat-lowering granule, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1537545A true CN1537545A (en) | 2004-10-20 |
| CN1291709C CN1291709C (en) | 2006-12-27 |
Family
ID=34319169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03108972 Expired - Lifetime CN1291709C (en) | 2003-04-15 | 2003-04-15 | Sugar-free type blood-fat-lowering granule, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1291709C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266532A (en) * | 2011-07-27 | 2011-12-07 | 张秀兰 | Medicament for treating fatty liver and preparation method thereof |
| CN104225206A (en) * | 2014-07-23 | 2014-12-24 | 江苏七O七天然制药有限公司 | Sugar-free Changchun longevity granules and preparation method thereof |
| CN104474169A (en) * | 2014-12-16 | 2015-04-01 | 山东京御堂国药有限公司 | Radix puerariae-hawthorn lipid-reducing granules and preparation method thereof |
| CN104491239A (en) * | 2014-12-16 | 2015-04-08 | 山东京御堂国药有限公司 | Traditional Chinese medicine composition for reducing fat and preparation thereof |
| CN104510857A (en) * | 2014-12-16 | 2015-04-15 | 山东京御堂国药有限公司 | Traditional Chinese medicinal effective part composition for lowering lipid and preparations of traditional Chinese medicinal effective part composition |
| CN104623136A (en) * | 2015-01-12 | 2015-05-20 | 李元勋 | Traditional Chinese medicine health product for assisting blood-lipid reduction, namely angelica sinensis and astragalus membranaceus blood-lipid reducing granules and preparation method thereof |
| CN107184752A (en) * | 2017-06-07 | 2017-09-22 | 广西中医药大学第附属医院 | A kind of blood fat regulating capsule and preparation method thereof |
-
2003
- 2003-04-15 CN CN 03108972 patent/CN1291709C/en not_active Expired - Lifetime
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266532A (en) * | 2011-07-27 | 2011-12-07 | 张秀兰 | Medicament for treating fatty liver and preparation method thereof |
| CN102266532B (en) * | 2011-07-27 | 2013-12-11 | 张秀兰 | Medicament for treating fatty liver and preparation method thereof |
| CN104225206A (en) * | 2014-07-23 | 2014-12-24 | 江苏七O七天然制药有限公司 | Sugar-free Changchun longevity granules and preparation method thereof |
| CN104474169A (en) * | 2014-12-16 | 2015-04-01 | 山东京御堂国药有限公司 | Radix puerariae-hawthorn lipid-reducing granules and preparation method thereof |
| CN104491239A (en) * | 2014-12-16 | 2015-04-08 | 山东京御堂国药有限公司 | Traditional Chinese medicine composition for reducing fat and preparation thereof |
| CN104510857A (en) * | 2014-12-16 | 2015-04-15 | 山东京御堂国药有限公司 | Traditional Chinese medicinal effective part composition for lowering lipid and preparations of traditional Chinese medicinal effective part composition |
| CN104491239B (en) * | 2014-12-16 | 2016-03-16 | 山东京御堂国药有限公司 | A kind of Chinese medicine composition for blood fat reducing and preparation thereof |
| CN104623136A (en) * | 2015-01-12 | 2015-05-20 | 李元勋 | Traditional Chinese medicine health product for assisting blood-lipid reduction, namely angelica sinensis and astragalus membranaceus blood-lipid reducing granules and preparation method thereof |
| CN104623136B (en) * | 2015-01-12 | 2018-08-28 | 李元勋 | A kind of auxiliary antilipemic Chinese herbal medicine health products Radix Angelicae Sinensis Radix Astragali blood-fat-lowering granule and preparation method thereof |
| CN107184752A (en) * | 2017-06-07 | 2017-09-22 | 广西中医药大学第附属医院 | A kind of blood fat regulating capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1291709C (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1586544A (en) | Medicinal wine and its producing method | |
| CN102233119A (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN108404062B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method and application thereof | |
| CN100493518C (en) | A blood fat-decreasing traditional Chinese medicine and preparation method thereof | |
| CN101496894B (en) | Medicament for treating fatty liver and preparation method thereof | |
| CN1291709C (en) | Sugar-free type blood-fat-lowering granule, and its prepn. method | |
| CN102319357B (en) | Lipid-lowering dispersible tablets and preparation technology thereof | |
| CN102488798A (en) | Medicine for treating non-alcoholic fatty liver | |
| CN103372073A (en) | Red rice and hawthorn medicinal composition for regulating blood fat and preparation method of composition | |
| CN1136902C (en) | Prepn. of wetness-evil eliminating and dyspepsia relieving medicine tablet | |
| CN1283288C (en) | Composition of medicine for lowering fat, and its prepn. method | |
| CN111803600A (en) | Traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease and preparation method | |
| CN111110735A (en) | Lipid-lowering pharmaceutical composition, preparation method and application | |
| CN106266949A (en) | A kind of compound Chinese medicinal preparation and its preparation method and application | |
| CN101020016B (en) | Medicine for treating fracture and injured tendon and its preparation | |
| CN102008598A (en) | Blood fat-lowering and liver-protecting composite as well as preparation prepared thereby and preparation method of preparation | |
| CN100409880C (en) | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same | |
| CN1087627C (en) | Medicament for treating diabetes and its preparation method | |
| CN101797365B (en) | Preparation technology of Kaixiong Shunqi Jiaonang | |
| CN105213748A (en) | A kind of pharmaceutical composition for the treatment of female dimacteric syndrome and preparation method thereof | |
| CN105194131A (en) | Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof | |
| CN104257839A (en) | Traditional Chinese medicine composition with effects of reducing blood glucose and blood fat and protecting vascular endothelium and preparation method thereof | |
| CN1079262C (en) | Pregnancy promoting medicine to treat man's and woman's sterility and its preparation | |
| CN111000969A (en) | Pharmaceutical composition for treating simple obesity and preparation method thereof | |
| CN1186038C (en) | Capsule for curing aplastic anemia and its production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Anhui Academy of Medical Sciences Document name: Notification of acceptance |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LVYIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ANHUI PROVINCE MEDICINE SCIENCE INSTITUTE; SANJIU PHARMACEUTICAL CO., LTD. Effective date: 20071123 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20071123 Address after: Linyi hi tech Industrial Development Zone, Shandong, China: 276017 Patentee after: SHANDONG LUYIN PHARMACEUTICAL Address before: No. 15, Yonghong Road, Hefei, Anhui: 230061 Co-patentee before: Sanjiu Medical & Pharmaceutical Co.,Ltd. Patentee before: Anhui Prov. Medical Science Research Inst. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG JINGYUTANG TRADITIONAL CHINESE MEDICINE C Free format text: FORMER OWNER: SHANDONG LUYIN PHARMACEUTICAL CO., LTD. Effective date: 20131204 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 276015 LINYI, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131204 Address after: 276015 south section of industry road three, Ma Hu Town, hi tech Development Zone, Shandong, Linyi Patentee after: JINGYUTANG PHARMACEUTICAL CO.,LTD. Address before: 276017 hi tech Industrial Development Zone, Shandong, Linyi Patentee before: SHANDONG LUYIN PHARMACEUTICAL |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20220830 Address after: 276600 west side of the middle section of Gongye Third Road, high tech Zone, Linyi City, Shandong Province Patentee after: Shandong jingyutang Pharmaceutical Co.,Ltd. Address before: 276015 south section of Gongye 3rd road, machanghu Town, high tech Development Zone, Linyi City, Shandong Province Patentee before: JINGYUTANG PHARMACEUTICAL CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061227 |
|
| CX01 | Expiry of patent term |